What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
October 29, 2025 | Obesity Week, cardiometabolic health
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
Authored by: Varun Renjen, Lisa Gallacher, and Brandon Boland
How Inizio experts see the next era of obesity care – and what it means for pharma leadership.
As obesity science continues to evolve, so too does the opportunity for pharma to lead with purpose. Obesity Week 2025 will spotlight this evolution – showcasing how obesity has moved beyond weight loss alone to become a driver of cardiometabolic health.
For Inizio experts Varun Renjen (Partner, Inizio Advisory), Lisa Gallacher (SVP, European Science Lead, Inizio Medical), and Brandon Boland (EVP, Global Biotechnology Portfolio Lead, Inizio Medical), leadership in this fast-changing field means connecting strategy, science, and execution to deliver purposeful progress.
“Obesity has broken out of the shadows of other conferences where it was often an after-thought”,” says Varun Renjen. “This is probably going to be the most relevant conference moving forward for obesity.”
Obesity in the spotlight: From niche to necessity
Once a sub-track at diabetes meetings, Obesity Week has become the premier global congress for this fast-moving therapeutic area.
“It has eclipsed ENDO in priority for our clients,” explains Brandon Boland. “Obesity Week puts obesity in the spotlight.”
That prominence reflects a therapeutic area maturing at pace. Conversations are shifting toward the quality of weight loss versus quantity, the impact on comorbidities, and how new treatment paradigms can deliver sustained outcomes.
“The co-morbidities aspect is key,” adds Lisa Gallacher. “We’re learning more about how obesity therapies can support broader health outcomes – including inflammation, cardiovascular function, and even cognitive health – alongside weight management.”
Evolving science, evolving strategy
As new drug classes expand the landscape – GLP-1s, amylins, dual and multi-agonists – precision medicine and patient segmentation are shaping the next frontier of obesity care.
“The big question is how do we treat such a heterogenous disease within such a large population,” says Varun. “Some will respond better to GLP-1s, others to amylin or dual agonists… a post-menopausal woman will have different clinical needs than a younger man in his 20s. We need to be able to triangulate patient populations and be able to treat more precisely across the whole treatment journey continuum.”
Pharma organizations are also recalibrating commercial strategies around these scientific shifts.
“Clients are vying for patients, trial sites, and share of voice,” says Brandon. “Obesity Week is a chance to gain stature with experts and capture key resources – awareness, asset differentiation, and competitive intelligence all matter.”
Navigating a crowded market with purpose
The obesity market could exceed $100 billion within the decade, but growth brings challenges. Regulatory uncertainty, payer access, and biosimilar pressure are all influencing development and launch decisions.
“There’s regulatory uncertainty in the U.S.,” explains Brandon Boland. “Physicians are balancing how best to integrate weight management and comorbidity care to support overall health and quality of life while maintaining therapy access for their patients.”
“Given how much spend and market demand is anticipated, access will become more challenging,” adds Varun. “But there are creative ways to navigate this through thoughtful portfolio, development, and commercial go to market strategies to ensure a patient can access therapy.”
At Inizio, we help clients simplify this complexity – bringing clarity and cohesion across the full product lifecycle. Our connected approach unites Medical Affairs, strategy, engagement, and technology, enabling teams to move from science to impact.
“It’s about agility in execution,” says Brandon. “Helping clients focus on the mandatories and not get distracted by the noise.”
From obesity to cardiometabolic health
The field’s very definition is expanding.
“The term obesity might evolve over time to cardiometabolic dysfunction,” says Varun. “Treating obesity supports the body from head to toe through one pathway – approvals in kidney, liver, sleep, and even dementia show how interconnected these systems are. Obesity is a complex disease that requires more than a focus on weight reduction – it’s about improving overall metabolic health, as well as preventing and slowing down end organ damage. This is a change of how we think of treating patients not just as treating one disease or one organ but treating the whole patient.”
That shift is echoed across industry communications and R&D focus areas.
“It’s becoming beyond obesity,” adds Lisa. “Clients are reframing around cardio-kidney-metabolic health and other comorbidities. That’s where the conversation is heading.”
And new therapeutic innovations will accelerate it.
“Very soon, multi-agonists will eclipse monotherapies,” predicts Brandon. “Clients need to keep a portfolio approach and not neglect the comorbidities.”
Turning strategy into impact
For Inizio, supporting clients in obesity means helping them anticipate the future – and act on it now.
“We bring full end-to-end development, medical, and commercialization expertise,” says Varun. “And a unified vision of how to own the patient journey across the treatment continuum.”
Whether it’s building purposeful portfolios or shaping the narrative from obesity to cardiometabolic health, Inizio partners to deliver measurable progress. Through Intelligent Commercialization™ – our expert-driven framework connecting data, technology, and AI – we help clients turn scientific innovation into scalable, lasting impact.
As the industry gathers at Obesity Week 2025, we’ll be at booth 812, ready to connect with partners and peers who share our vision of turning science into impact – simplifying complexity, amplifying purpose, and helping clients lead where it matters most.
Get in touch to meet with us at the event or learn more about how we deliver impact across obesity and cardiometabolic health here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Pegasus scoops five ‘Consultancy’ wins, making 2016 a stellar year for the health comms consultancy
Pegasus, an Ashfield company, part of UDG Healthcare plc, last night scooped its fifth ‘consultancy’ award of the year at the PRCA Awards in London’s Park Lane where it secured...
Free Thinking – US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare
Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare
Pegasus crowned PR Week’s Specialist Consultancy of the Year, making a hat-trick of Consultancy wins in 2016!
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have been crowned Specialist Consultancy of the Year at this week’s prestigious PR Week Awards. The accolade tops...
Therapy Watch market snapshots
Therapy Watch is a ‘real-time’ syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed,...
Case Study: Private market opportunity for a travel vaccine
Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine:Which markets had the highest potential to...
Infographic: Conference Live
Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...
Blog: The Cost of Counterfeits
The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.
Video: Self-pay and Emerging Markets
A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...
News: Therapy Watch HCV expands into 4 additional EU markets
The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...
News: Research Partnership launches new patient report – Living with Ulcerative Colitis
Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...